68 research outputs found

    Povratak u budućnost psihofarmakologije Natrijev benzoat

    Get PDF
    A section focused on potential and new psychopharmacologic treatment optionsRubrika o potencijalnim i novim psihofarmakološkim terapijskim opcijam

    AMENORRHOEA – CONSEQUENCE OF COMBINED TREATMENT WITH SULPIRIDE AND RISPERIDONE IN A PATIENT SUFFERING FROM SCHIZOPHRENIA

    Get PDF
    It is well documented that sulpiride causes hormonal adverse events, like amenorrhoea and galactorrhea, due to its mechanism of action. Furthermore, risperidone can produce amenorrhoea and galactorrhea also, due to its mechanism of action, which differs from that of sulpiride. This case report is of a patient that was treated with large doses of sulpiride, but did not develop an adverse event like amenorrhoea. However, when risperidone was introduced into therapy it leads to the onset of amenorrhoea. Gynecologist saw it as the beginning of menopause. General practitioner questioned the existence of an intra-cerebral process that could produce amenorrhoea as well. Therefore, the patient was sent to perform an MRI of the brain, under work diagnosis of pituitary adenoma, which was later ruled out as a cause of the illness. Well experienced psychiatrist linked the loss of menstruation with the adverse event profile of sulpiride and therefore gradually discontinued sulpiride from therapy, while risperidone was left and subsequently menstrual cycle was restored. Good knowledge of adverse events profile of antipsychotic medication used, especially when used in a combination, allows us to correctly question appearance of adverse events, to adequately treat them and lowers the cost of unneeded medical procedures

    Casein Kinase 1 Modulator PF-05251749

    Get PDF
    Back to the Future of Psychopharmacology Regular section of the journal focusing on new and potential treatment options in psychiatry

    AMENORRHOEA – CONSEQUENCE OF COMBINED TREATMENT WITH SULPIRIDE AND RISPERIDONE IN A PATIENT SUFFERING FROM SCHIZOPHRENIA

    Get PDF
    It is well documented that sulpiride causes hormonal adverse events, like amenorrhoea and galactorrhea, due to its mechanism of action. Furthermore, risperidone can produce amenorrhoea and galactorrhea also, due to its mechanism of action, which differs from that of sulpiride. This case report is of a patient that was treated with large doses of sulpiride, but did not develop an adverse event like amenorrhoea. However, when risperidone was introduced into therapy it leads to the onset of amenorrhoea. Gynecologist saw it as the beginning of menopause. General practitioner questioned the existence of an intra-cerebral process that could produce amenorrhoea as well. Therefore, the patient was sent to perform an MRI of the brain, under work diagnosis of pituitary adenoma, which was later ruled out as a cause of the illness. Well experienced psychiatrist linked the loss of menstruation with the adverse event profile of sulpiride and therefore gradually discontinued sulpiride from therapy, while risperidone was left and subsequently menstrual cycle was restored. Good knowledge of adverse events profile of antipsychotic medication used, especially when used in a combination, allows us to correctly question appearance of adverse events, to adequately treat them and lowers the cost of unneeded medical procedures

    Zuranolone

    Get PDF
    Zuranolone is an oral neuroactive steroid under development by Sage Therapeutics and Biogen (SAGE-217/BIIB125). It is currently being evaluated as a treatment option for postpartum depression (PPD) and major depressive disorder (MDD) [1]. MDD is one of the most frequent mental disorders; for example, in the United States, it affects more than 8 % of adults every year. On the other hand, PPD is one of the most common medical complications during and after pregnancy and is estimated to affect approximately one in eight women who have given birth. Although clinical presentation of MDD and PPD varies, patients frequently experience feelings of hopelessness, anxiety or sadness which, consequently, affect their quality of life, in terms of ability to work, maintenance of relationships and school attendance. In severe cases, risk of suicide can be substantial. As for the treatment of these disorders, current guidelines include a multitude of approved antidepressants which can help alleviate symptoms for most patients. However, these medications in general require four to six weeks to work. In translation that means patients must endure their symptoms for a month or more after starting a treatment to see if it helps

    Paliperidone Palmitate 6-month (PP6M)

    Get PDF
    Back to the Future of Psychopharmacolog

    Croatian Society for Schizophrenia and Schizophrenia Spectrum Disorders Croatian Medical Association Guidelines for the Treatment of Patients with Schizophrenia Spectrum Disorders during the COVID-19 Pandemic

    Get PDF
    Recommendations for treatment of patients suffering from schizophrenia and schizophrenia spectrum disorders during the COVID-19 pandemic, with an emphasis on potential interactions between different psychopharmaceuticals and medications most commonly used to treat COVID-19 infection

    Inhibitori ponovnog unosa glicina

    Get PDF
    Back to the Future of Psychopharmacology The section about new and potential psychopharmacologic treatments in psychiatry.Povratak u budućnost psihofarmakologije. Rubrika o novim i potencijalnim molekulama za primjenu u psihijatriji

    Daridorexant

    Get PDF
    Daridorexant belongs to a class of drugs known as dual orexin receptor (OX1R and OX2R) antagonists. It achieves its function by blocking the binding of wake-promoting neuropeptides orexins. This novel mechanism is believed to turn down overactive wakefulness and as we know so far, most other treatments for insomnia can be sedating
    • …
    corecore